Health · United States of America
FDA requires GLP-1 drug warnings over rare condition linked to vision loss
The regulator identified a potential increase in NAION risk after reviewing clinical trials. An ophthalmology group says any additional risk appears small and causation remains unproven.
The FDA is requiring GLP-1 drug labels to warn about potential NAION risk. Whether the medicines cause the rare eye condition remains unresolved.
- NAION can cause permanent vision loss.
- The FDA review identified 15 probable cases across 126 trials.
- The ophthalmology academy says any added risk appears small.
- Patients should consult their doctor before stopping medication, the academy says.
What's new
- The FDA is requiring NAION risk information on all GLP-1 drug labels.
- Its trial review identified 15 probable cases, including 10 among GLP-1 recipients.
- The agency says it is not known why users may face greater risk.
The US Food and Drug Administration is requiring warnings on GLP-1 medicines about a rare eye condition that can permanently impair vision, according to reports published on November 10, 2026. The US action covers drugs including Ozempic, Wegovy, Mounjaro and Zepbound, following a review that identified a potential increase in risk.12
What the warning covers
The condition, nonarteritic anterior ischemic optic neuropathy, or NAION, involves an abrupt fall in blood flow to the optic nerve, according to the Guardian’s account. It can produce sudden, painless loss of vision in one eye. There is currently no treatment that reverses the resulting vision loss.12
The Guardian reported that the FDA is requiring information about the potential risk in the warnings and precautions section of labels for all GLP-1 receptor agonists. The agency said cases had been reported across every currently marketed product in that drug class.1
According to the Guardian, GLP-1 medicines are used primarily to control blood sugar in people with type 2 diabetes, while some are also used to treat obesity. The BBC reported that the FDA said both obesity and type 2 diabetes could contribute NAION risk factors independently of the medicines.12
The evidence reviewed
The FDA examined 126 clinical trials covering more than 134,200 patients, according to the Guardian. It identified 15 probable NAION cases: 10 in patients receiving GLP-1 medicines and five in patients receiving a placebo. For every 100,000 person-years, the incidence rate was 6.4 among patients given GLP-1 medicines and 3.8 among those in the comparison group.1
The Guardian reported that the agency began investigating a possible connection following a study published in 2024. Separately, the BBC described research involving 17,000 patients in which semaglutide users were four times as likely to receive a NAION diagnosis. Study author Dr Joseph Rizzo called those findings “significant but tentative” and said research in a more diverse population was needed.12
Causation remains unresolved
According to the BBC, the FDA said the reason GLP-1 users may have a higher risk remains unclear. The American Academy of Ophthalmology said any additional risk appeared small and that the medicines had not been established as a cause of NAION.2
Novo Nordisk disputed a causal interpretation, saying the data “do not establish a cause-and-effect relationship”. The company said it continued to monitor medicine safety and assess new research. The ophthalmology academy noted that the medicines can help patients with diabetes, obesity and cardiovascular disease, and urged them to speak with their doctor before stopping treatment.12
Why it matters
For European readers, the BBC also reported an estimate from the European Medicines Agency’s safety arm that NAION may affect up to one in 10,000 semaglutide users. The uncertainty over causation remains relevant alongside that estimate; the American Academy of Ophthalmology advises patients to discuss medication decisions with their doctor.2
Videos
Version history
- version 1 ·